Clinical Neurochemistry Laboratory, Institute of Neuroscience & Physiology, Department of Psychiatry & Neurochemistry, The Sahlgrenska Academy at University of Gothenburg, Sahlgrenska University Hospital, Mölndal, Sweden.
Biomark Med. 2012 Aug;6(4):401-7. doi: 10.2217/bmm.12.41.
Cerebrospinal fluid (CSF) biomarkers are increasingly used for diagnosis of Alzheimer's disease in research, clinical trials and clinical settings. As for other biochemical measurements, variability between laboratories for these biomarkers may be monitored by proficiency testing programs, where participating laboratories use their local routine methods to analyze test samples shipped from a central laboratory. In this review, we summarize the results from the last years' pilot proficiency programs and describe the ongoing standardization efforts in this area. Global proficiency testing for CSF biomarkers is now fully established. It will continue to play an important part in the standardization of measurements that is a prerequisite for the broad-scale future implementation of CSF biomarkers.
脑脊液（CSF）生物标志物越来越多地用于研究、临床试验和临床环境中的阿尔茨海默病诊断。与其他生化测量一样，这些生物标志物的实验室间变异性可以通过能力验证计划进行监测，在该计划中，参与实验室使用其当地的常规方法分析从中央实验室发送的测试样本。在这篇综述中，我们总结了过去几年试点能力验证计划的结果，并描述了该领域正在进行的标准化工作。全球 CSF 生物标志物能力验证现已全面建立。它将继续在测量标准化方面发挥重要作用，这是 CSF 生物标志物广泛应用的前提。
